Jinqirui and Illumina's Co-Developed Benchtop High-Throughput Sequencer KM MiniSeqDx-CN Receives NMPA Approval

Sequencing China, April 10, 2020: The “KM MiniSeqDx-CN Gene Sequencer,” a desktop high-throughput sequencer co-developed by Guangzhou KingCreate Biotechnology Co., Ltd. and Illumina, has been officially approved for market launch by the National Medical Products Administration (NMPA).

Figure: Notice of Production Approval from the National Medical Products Administration (NMPA)

Figure: KM MiniSeqDx-CN Gene Sequencer

The KM MiniSeqDx-CN Gene Sequencer is a desktop high-throughput gene sequencer developed collaboratively by Guangzhou KingCreate Biotechnology Co., Ltd. and Illumina, based on Illumina’s core technology. It is reported thatThis device leverages Illumina’s proprietary dual-channel “Sequencing by Synthesis (SBS)” and “paired-end sequencing” core technologies, combined with Guangzhou KingCreate Biotechnology’s extensive expertise in the in vitro diagnostics (IVD) field., featuring flexible throughput, stable performance, precise data, user-friendly operation, and strong compatibility, this is an economical, flexible, and efficient high-throughput gene sequencer developed by Guangzhou KingCreate Biotechnology Co., Ltd. and Illumina for the Chinese clinical market.

The approval of the KM MiniSeqDx-CN Gene Sequencer provides a convenient, reliable, rapid, and cost-effective solution for clinical diagnostics and research, offering a high-quality option specifically for conducting tumor companion diagnostic tests within hospitals.Currently, Guangzhou KingCreate Biotechnology Co., Ltd. has successfully independently developed multiple tumor gene detection kits on this platform., including lung cancer, colorectal cancer, breast cancer, ovarian cancer, and other cancer types, covering clinical application areas such as early screening, medication guidance, and prognosis.。

Figure: KM MiniSeqDx-CN System Performance Parameters

Guangzhou KingCreate Biotechnology Co., Ltd. is committed to comprehensively advancing technological incubation and commercialization in the high-end IVD sector through win-win collaboration, technological innovation, and efficient operations, with the goal of building a leading domestic platform for precision medicine in vitro diagnostic products. The company aims to become a provider of comprehensive solutions in the fields of precision medicine and tumor companion diagnostics in China, empowering healthcare institutions at all levels to deliver efficient and precise personalized medical solutions to patients.

Dr. Hu Zhaohui, Founder and Executive Director of KingCreate BiotechnologyGuangzhou KingCreate Biotechnology Co., Ltd. stated that it will continue to uphold its customer-centric, clinically oriented mission, leverage its strengths, collaborate with leading international research institutions, integrate global innovative resources, and continuously expand and enhance its IVD product portfolio, thereby contributing to the advancement of precision medicine in China and benefiting Chinese patients.